Canagliflozin extends life span in genetically heterogeneous male but not female mice

Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and kidney diseases. It also inhibits the sodium glucose transporter 2 by blocking renal reuptake and intestinal absorption of glucose. In the context of the mouse Interventions Testing Program, genetically he...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JCI Insight
Κύριοι συγγραφείς: Miller, Richard A., Harrison, David E., Allison, David B., Bogue, Molly, Debarba, Lucas, Diaz, Vivian, Fernandez, Elizabeth, Galecki, Andrzej, Garvey, W. Timothy, Jayarathne, Hashan, Kumar, Navasuja, Javors, Martin A., Ladiges, Warren C., Macchiarini, Francesca, Nelson, James, Reifsnyder, Peter, Rosenthal, Nadia A., Sadagurski, Marianna, Salmon, Adam B., Smith, Daniel L., Snyder, Jessica M., Lombard, David B., Strong, Randy
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Clinical Investigation 2020
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710304/
https://ncbi.nlm.nih.gov/pubmed/32990681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.140019
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια